73.79
전일 마감가:
$72.84
열려 있는:
$73.7
하루 거래량:
3.43M
Relative Volume:
0.68
시가총액:
$228.77B
수익:
$54.07B
순이익/손실:
$7.04B
주가수익비율:
32.72
EPS:
2.255
순현금흐름:
$7.28B
1주 성능:
-1.52%
1개월 성능:
-2.46%
6개월 성능:
-4.93%
1년 성능:
+8.92%
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
73.79 | 228.77B | 54.07B | 7.04B | 7.28B | 2.255 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
2025-02-12 | 개시 | Morgan Stanley | Overweight |
2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-05-30 | 개시 | Goldman | Buy |
2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Sell |
2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
2023-12-18 | 개시 | HSBC Securities | Buy |
2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | 개시 | BMO Capital Markets | Outperform |
2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | 업그레이드 | Argus | Hold → Buy |
2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
2021-08-12 | 재개 | JP Morgan | Overweight |
2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
2020-09-29 | 개시 | Berenberg | Buy |
2019-11-22 | 개시 | SVB Leerink | Outperform |
2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
2018-02-05 | 재확인 | Bernstein | Outperform |
2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.
AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues
AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha
AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus.com
Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360
Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK
Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK
AstraZeneca Fights Generic Diabetes Drug Launch - Law360
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance
Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com
Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360
J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business
J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga
J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - Bloomberg
AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India
Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg
Whittier Trust Co. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld Online
Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - Marketscreener.com
AstraZeneca Seeks to Move Past China Probe With R&D Hub - Bloomberg
AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia
AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors UK
Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo Finance UK
AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology
Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - Marketscreener.com
Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca Expands Emphasis On China, Already A Key Market - News & Insights
AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch
Sector Update: Health Care Stocks Retreat Late Afternoon -March 21, 2025 at 03:50 pm EDT - Marketscreener.com
AstraZeneca to invest $2.5bn in China after snub for UK plant - The Times
AstraZeneca To Invest $2.5B In China Research Hub - Law360
Sector Update: Health Care Stocks Fall in Afternoon Trading -March 21, 2025 at 01:50 pm EDT - Marketscreener.com
Sector Update: Health Care -March 21, 2025 at 01:39 pm EDT - Marketscreener.com
Going in vivo: AstraZeneca acquires EsoBiotec in potential $1bn deal - BioXconomy
AstraZeneca deepens China investment; Editas loses CFO to Dyne - BioPharma Dive
HBM Holdings To Issue To Astrazeneca Holdings Subscription Shares -March 21, 2025 at 11:28 am EDT - Marketscreener.com
Kangtai Biological Products To Establish JV With AstraZeneca -March 21, 2025 at 10:40 am EDT - Marketscreener.com
AstraZeneca to invest £2bn in Beijing amid China investigation - Yahoo Finance
Micron, Johnson & Johnson, AstraZeneca: Top Stocks - Yahoo Finance
Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed - BioWorld Online
AstraZeneca to make a $2.5B investment in China (AZN:NASDAQ) - Seeking Alpha
AstraZeneca invests US$2.5 bil in Beijing hub amid probe - The Edge Malaysia
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):